DealsJul 20, 2026, 07:01 AM
Kamada Secures 3-Year, $50M Plasma Supply Agreement
AI Summary
Kamada Ltd. announced a three-year sales agreement to supply normal source plasma to a leading biopharmaceutical company. This agreement is expected to generate approximately $50 million in revenue over its duration, with initial commercial sales anticipated in the fourth quarter of 2026. The company stated that these expected sales are already factored into its current annual guidance, and the deal validates its investment in U.S.-based plasma collection centers, supporting its vertical integration strategy and revenue growth.
Key Highlights
- Kamada secured a three-year sales agreement to supply normal source plasma.
- The agreement is valued at approximately $50 million in revenue.
- Initial commercial sales are expected to be recorded in Q4 2026.
- Plasma will be supplied from Kamada's FDA-approved collection centers in Texas.
- Each collection center has a planned capacity of approximately 50,000 liters per year.
- The agreement supports Kamada's vertical integration and revenue growth objectives.
Price Impact
More from KMDA